Previous 10 | Next 10 |
CorMedix (CRMD): Q3 GAAP EPS of -$0.22 beats by $0.04.Revenue of $0.93M (+1450.0% Y/Y) beats by $0.89M.Shares +1.5% AH.Press Release For further details see: CorMedix EPS beats by $0.04, beats on revenue
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial result...
BERKELEY HEIGHTS, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment ...
BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will rep...
Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers
Citius Pharmaceuticals is nearing the completion of its Phase 3 trail with top-line data due Dec 2020 (or sooner). Mino-Lok fills an unmet medical need in the CRBSI space for Central Venous Catheters with potential annual US sales of $500M. The Chairman of the Board has extensive ...
BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Matt David,...
U.S. Energy (USEG) +168% after entering producing assets purchase agreement.Houston American Energy (HUSA) +77%.PEDEVCO (PED) +56%.Greenpro Capital Corp. (GRNQ) +53%.Flux Power Holdings (FLUX) +36% on FY results.Mexco Energy (MXC) +33%.Westwater Resources (WWR) +30%.New Co...
Truist initiated CorMedix ([[CRMD]] +12.9%) with a Buy rating, PT $20 indicating a more than four times increase from current levels.In the past 6-months, the stock has surged 96.2%; quick look at the company's total return vs. broader index performance (IYH):Analyst Joon Lee contends that th...
BERKELEY HEIGHTS, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...